Delavirdine can cause serious, life-threatening side effects. This includes severe skin rash.
If you have a severe skin rash or have any of the following symptoms along with a skin rash, stop taking delavirdine and contact your health care provider right away:
Taking certain medicines with delavirdine may cause serious, life-threatening side effects. Tell your health care provider about all medicines you are taking or planning to take before you take delavirdine.
While taking delavirdine, it is important to keep all of your appointments with your health care provider.
Delavirdine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults. Delavirdine is always used in combination with other HIV medicines.
Delavirdine belongs to a class (group) of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). NNRTIs attach to and block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking reverse transcriptase, NNRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.
HIV medicines can’t cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission.
Before taking delavirdine, tell your health care provider:
Delavirdine comes in tablet form in two strengths:
Take delavirdine according to your health care provider’s instructions.
You may take delavirdine with or without food. Taking delavirdine on a regular schedule along with activities you do every day, such as getting up in the morning, brushing your teeth, eating lunch, coming home from work in the evening, or watching a favorite TV show, will make it easier to remember to take every dose.
If you are taking both delavirdine and antacids, take them at least 1 hour apart. If your health care provider has told you that you don’t have enough stomach acid, take delavirdine with orange or cranberry juice.
If you have trouble swallowing tablets, the 100-mg delavirdine tablets may be dissolved in water. Add four tablets to at least 3 ounces of water. Allow the tablets to sit in the water for a few minutes. Stir the water until the tablets have dissolved and then drink the delavirdine-water mixture right away. Rinse the glass and swallow the rinse to make sure that you get all the medicine. Delavirdine 200-mg tablets cannot be dissolved in water and must be swallowed whole.
Always take delavirdine in combination with other HIV medicines.
If you take too much delavirdine, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.
For more information on how to take delavirdine, see the FDA drug label from DailyMed. (DailyMed is a federal website that includes the most recent drug labels submitted to FDA.)
If you miss a dose of delavirdine, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
Delavirdine can cause serious, life-threatening side effects. This includes severe skin rash. (See the WARNING above.)
Other possible side effects of delavirdine include:
Tell your health care provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of delavirdine. To learn more about possible side effects of delavirdine, read the drug label or package insert or talk to your health care provider or pharmacist.
The AIDSinfo fact sheet on HIV Medicines and Side Effects also includes information that may apply to delavirdine.
You can also report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or online at https://www.accessdata.fda.gov/scripts/medwatch/.
More information about delavirdine is available:
Last Reviewed: October 9, 2014
Last Updated: October 9, 2014